Literature DB >> 17318853

Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors.

Michael Olausson1, Styrbjörn Friman, Gustaf Herlenius, Christian Cahlin, Ola Nilsson, Svante Jansson, Bo Wängberg, Håkan Ahlman.   

Abstract

Liver transplantation can be a therapeutic option for individual patients with neuroendocrine tumors metastatic only to the liver. In this consecutive series of 15 patients (5 multivisceral and 10 orthotopic liver transplantations) with well-differentiated carcinoids, or endocrine pancreatic tumors, we allowed higher proliferation rate (Ki67 <10%), large tumor burden, and higher age than previous studies. Liver transplantation offered good relief of symptoms, long disease-free intervals, and potential cure in individual patients. The survival of grafts and patients compared well with transplantation for benign disease. The overall 5-year survival was 90%. The recurrence-free survival of both multivisceral and liver transplantation related to the time after transplantation (about 20% at 5 years) despite inclusion of patients with higher risk. In conclusion, the critical prognosticators for long-term outcome still remain to be defined. The experience with multivisceral transplantation for patients with endocrine tumors of the pancreatic head is still limited. (c) 2007 AASLD.

Entities:  

Mesh:

Year:  2007        PMID: 17318853     DOI: 10.1002/lt.21056

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  34 in total

1.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.

Authors:  Matthew H Kulke; Lowell B Anthony; David L Bushnell; Wouter W de Herder; Stanley J Goldsmith; David S Klimstra; Stephen J Marx; Janice L Pasieka; Rodney F Pommier; James C Yao; Robert T Jensen
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

Review 2.  Surgical management of neuroendocrine tumor-associated liver metastases: a review.

Authors:  Miu Yee Chan; Ka Wing Ma; Albert Chan
Journal:  Gland Surg       Date:  2018-02

3.  Liver transplantation for metastatic neuroendocrine tumors: Outcomes and prognostic variables.

Authors:  Linda S Sher; David M Levi; Julie S Wecsler; Mary Lo; Lydia M Petrovic; Susan Groshen; Lingyun Ji; Teresa Diago Uso; A Joseph Tector; Ann S Hamilton; J Wallis Marsh; Myron E Schwartz
Journal:  J Surg Oncol       Date:  2015-07-14       Impact factor: 3.454

4.  Liver transplantation for symptomatic liver metastases of neuroendocrine tumours.

Authors:  G Chan; W Kocha; R Reid; A Taqi; W Wall; D Quan
Journal:  Curr Oncol       Date:  2012-08       Impact factor: 3.677

5.  Simultaneous pancreatectomy and liver transplantation: a single-institution experience.

Authors:  Rajeev Dhupar; Michael E de Vera; J Wallis Marsh; Paulo A Fontes; Jennifer L Steel; Herbert J Zeh; T Clark Gamblin
Journal:  HPB (Oxford)       Date:  2009-05       Impact factor: 3.647

6.  Liver transplantation for unresectable colorectal liver metastasis.

Authors:  Albert Chan
Journal:  Hepatobiliary Surg Nutr       Date:  2013-06       Impact factor: 7.293

Review 7.  Update on pancreatic neuroendocrine tumors.

Authors:  Logan R McKenna; Barish H Edil
Journal:  Gland Surg       Date:  2014-11

Review 8.  Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1.

Authors:  Kazuhiro Hanazaki; Akihiro Sakurai; Masaya Munekage; Kengo Ichikawa; Tsutomu Namikawa; Takehiro Okabayashi; Masayuki Imamura
Journal:  Surg Today       Date:  2012-10-19       Impact factor: 2.549

9.  Multivisceral transplantation: expanding indications and improving outcomes.

Authors:  Richard S Mangus; A Joseph Tector; Chandrashekhar A Kubal; Jonathan A Fridell; Rodrigo M Vianna
Journal:  J Gastrointest Surg       Date:  2012-10-16       Impact factor: 3.452

Review 10.  Liver transplantation for neuroendocrine tumour liver metastases.

Authors:  Sheung Tat Fan; Yves Patrice Le Treut; Vincenzo Mazzaferro; Andrew K Burroughs; Michael Olausson; Stefan Breitenstein; Andrea Frilling
Journal:  HPB (Oxford)       Date:  2014-07-03       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.